Late news: US FTC gives J&J (Johnson & Johnson) conditional approval for Guidant acquisition
This article was originally published in Clinica
Ending weeks of mounting anticipation, the US Federal Trade Commission (FTC) has finally given Johnson & Johnson conditional approval to go ahead with its proposed $25.4bn acquisition of Guidant - only for the healthcare group to state openly that it is now having second thoughts about going through with the deal.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.